Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy.

Journal of the American Academy of Dermatology - 1 May 2015

Anforth Rachael, Menzies Alexander, Byth Karen, Carlos Giuliana, Chou Shaun, Sharma Raghwa, Scolyer Richard A, Kefford Richard, Long Georgina V, Fernandez-Peñas Pablo

Abstract excerpt

BACKGROUND: BRAF inhibitors (BRAFi) cause paradoxical activation of the MAPK pathway in keratinocytes resulting in cutaneous squamous cell carcinoma (cuSCC). OBJECTIVE: We sought to examine the clinical factors involved in BRAFi-induced cuSCC development. METHODS: We studied 134 patients with BRAF-mutant metastatic melanoma treated with a BRAFi at Westmead Hospital, Sydney, Australia. Details of cuSCC development...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Indoles
Share to Biopsy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Squamous Cell

Share to Imidazoles

Share to Oximes

Share to Skin Neoplasms

Share to Sulfonamides

Share to Vemurafenib

Source

Identifiers

PMID: 25748298
DOI: 10.1016/j.jaad.2015.01.018

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy.PMID 25748298Read ↗

A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience.Semantic proximity Read ↗

BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site.Semantic proximity Read ↗

BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.Semantic proximity Read ↗

Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1.Semantic proximity Read ↗

Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis.Semantic proximity Read ↗

Cutaneous adverse events to type I BRAF inhibitors: an analysis of effects associated with each inhibitor and therapeutic time interval to onset.Semantic proximity Read ↗

Melanocytic nevi excised during B-Raf proto-oncogene (BRAF) inhibitor therapy: A study of 19 lesions from 10 patients.Semantic proximity Read ↗

BRAF mutational epidemiology in dysplastic nevi: does different solar UV radiation exposure matter?Semantic proximity Read ↗

Eruptive naevi in a patient treated with LGX818 for BRAF mutant metastatic melanoma.Semantic proximity Read ↗

Development of RET mutant cutaneous angiosarcoma during BRAF inhibitor therapy.Semantic proximity Read ↗

Absence of BRAF mutations in UV-protected mucosal melanomas.Semantic proximity Read ↗

Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.